secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2026-06-16T20:23:50+00:00
Accession:  0001841387-26-000007
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel Therapeutics formalizes CFO employment agreement with $468,600 salary, 40% target bonus
--------------------------------------------------------------------------------

- CFO Charles Schoch's new agreement sets base salary at $468,600 and target annual bonus at 40% of base.
- Severance on termination without cause or for good reason: 9 months base salary plus target bonus.
- Time-based equity awards fully accelerate if termination occurs within 1 month before or 12 months after change in control.
- Agreement includes standard confidentiality, non-compete, and non-solicitation covenants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000184138726000007/0001841387-26-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000184138726000007/cadl-20260612.htm
  HTML page:      https://secwatch.observer/filing/0001841387-26-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer